We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Facility Allows Immunology Specialists Access to Diagnostic Technology

By LabMedica International staff writers
Posted on 30 Mar 2009
Designed for use by clinical investigators and specialists in the field of immunology, new diagnostic technology characterizes a person's sensitization pattern at the molecular level.

The formal unveiling of the Phadia Immunology Reference Laboratory (PiRL) and its web site occurred at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology, held in Washington, DC (USA) from March 13-17, 2009. Phadia and National Jewish Health agreed to collaborate in the areas of education and research. This collaboration will support and advance the understanding of immunology by providing component-resolved diagnostics (CRD) at the molecular level utilizing ImmunoCAP technology.

ImmunoCAP technology was the first allergy test to be cleared by the US Food and Drug Administration (FDA; Rockville, MD, USA) as a truly quantitative test for pinpointing allergens. Allergy blood testing is recognized by the National Institutes of Health as an important tool in the everyday management of patients with asthma. ImmunoCAP technology measures IgE antibodies to outdoor, indoor, and food allergens in a small sample of blood. Specific IgE is produced as a result of sensitization to an allergen and increases with exposure to that substance.

"We are excited about the opportunity for Phadia and National Jewish Health to collaborate in the areas of education and research through the introduction of this new reference laboratory," said Michael Land, president of Phadia US. "By providing such advanced diagnostic services today for personalized patient care, we will one day be able to extend this understanding to a broader universe of clinicians, researchers, and patients."

PiRL is housed at Phadia's Portage, MI facility (UAS), and headed by medical director Henry Homburger, MD, who brings to PiRL a reputation for excellence in precision assay technology that optimizes diagnosis that enhances patient care.

Phadia AB, headquartered in Uppsala, Sweden, is the world leader in in-vitro IgE diagnostic research and product development.

Related Links:

Phadia Immunology Reference Laboratory
US Food and Drug Administration
Phadia



New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Tabletop Centrifuge
Mikro 185
New
Thyroxine ELISA
T4 ELISA

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients